CO6491045A2 - Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas - Google Patents
Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismasInfo
- Publication number
- CO6491045A2 CO6491045A2 CO12006115A CO12006115A CO6491045A2 CO 6491045 A2 CO6491045 A2 CO 6491045A2 CO 12006115 A CO12006115 A CO 12006115A CO 12006115 A CO12006115 A CO 12006115A CO 6491045 A2 CO6491045 A2 CO 6491045A2
- Authority
- CO
- Colombia
- Prior art keywords
- rsv
- methods
- protein
- compositions
- produce
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- -1 managed Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a composiciones inmunogénicas que comprenden proteína F de. RSV, a métodos para preparar composiciones que contienen polipéptidos de ecto-dominio de proteína F de RSV, y a ciertas proteínas F de RSV, manejadas, y ácidos nucleicos que codifican para las proteínas F de RSV, manejadas. Las composiciones preparadas usando los métodos pueden contener polipéptidos de ecto-dominio de proteína F de RSV en una forma y conformación deseada, individual o predominante. La invención también se refiere a métodos para inducir una respuesta inmunitaria a F de RSV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22580509P | 2009-07-15 | 2009-07-15 | |
US29442610P | 2010-01-12 | 2010-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6491045A2 true CO6491045A2 (es) | 2012-07-31 |
Family
ID=42834367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12006115A CO6491045A2 (es) | 2009-07-15 | 2012-01-17 | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas |
Country Status (22)
Country | Link |
---|---|
US (13) | US20120164176A1 (es) |
EP (6) | EP3178490B1 (es) |
JP (2) | JP5829210B2 (es) |
CN (2) | CN102639147B (es) |
AR (1) | AR077757A1 (es) |
BR (1) | BR112012001666A2 (es) |
CA (1) | CA2768186A1 (es) |
CL (1) | CL2012000119A1 (es) |
CO (1) | CO6491045A2 (es) |
DK (1) | DK3178490T3 (es) |
ES (2) | ES2918381T3 (es) |
HR (1) | HRP20220756T1 (es) |
HU (1) | HUE058971T2 (es) |
LT (1) | LT3178490T (es) |
MX (1) | MX2012000667A (es) |
PL (1) | PL3178490T3 (es) |
PT (1) | PT3178490T (es) |
RU (1) | RU2585227C2 (es) |
SG (1) | SG178026A1 (es) |
SI (1) | SI3178490T1 (es) |
TW (1) | TW201116294A (es) |
WO (1) | WO2011008974A2 (es) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
DK2370099T3 (en) * | 2008-12-09 | 2016-08-01 | Novavax Inc | Rsv f modified proteins and methods of their use |
HUE058971T2 (hu) | 2009-07-15 | 2022-09-28 | Glaxosmithkline Biologicals Sa | RSV F fehérjekészítmények és eljárások azok elõállítására |
EP2590670B1 (en) | 2010-07-06 | 2017-08-23 | GlaxoSmithKline Biologicals SA | Methods of raising an immune response by delivery of rna |
PL2590626T3 (pl) * | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
PT2590676T (pt) * | 2010-07-06 | 2016-11-04 | Glaxosmithkline Biologicals Sa | Partículas de transferência de tipo virião para moléculas de arn auto-replicante |
ES2938866T3 (es) | 2010-08-31 | 2023-04-17 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para la administración de ARN que codifica para inmunógeno |
PL4008357T3 (pl) | 2010-08-31 | 2023-03-06 | Glaxosmithkline Biologicals Sa | Małe liposomy do dostarczania rna kodującego immunogen |
JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
PL2667892T3 (pl) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | Schemat szczepień przeciwko rsv |
US9597390B2 (en) | 2011-03-02 | 2017-03-21 | Utrech University | Infectious bronchitis virus (IBV) spike protein as subunit vaccine |
BR112013024157A2 (pt) * | 2011-03-22 | 2016-12-06 | Mucosis Bv | composições imunogênicas em forma particulada e métodos para produção destas |
EP2688590B1 (en) * | 2011-03-24 | 2020-02-12 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with phospholipids |
ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
EP2729126B1 (en) | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes having useful n:p ratio for delivery of rna molecules |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
ES2705498T3 (es) * | 2011-08-31 | 2019-03-25 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para administración de ARN que codifica inmunógeno |
US9125870B2 (en) * | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
US10040828B2 (en) | 2012-04-10 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
CN109266622B (zh) | 2012-08-01 | 2023-05-09 | 巴法里安诺迪克有限公司 | 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗 |
SG11201500573RA (en) * | 2012-08-06 | 2015-02-27 | Glaxosmithkline Biolog Sa | Method for eliciting in infants an immune response against rsv and b. pertussis |
US20140037680A1 (en) * | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
MX2015006377A (es) * | 2012-11-20 | 2015-07-21 | Glaxosmithkline Biolog Sa | Trimeros prefusion de f de vsr. |
CA2897752A1 (en) * | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
DK2970398T3 (da) * | 2013-03-13 | 2024-08-05 | Us Health | Præfusions-rsv-f-proteiner og anvendelse deraf |
AU2014239583B2 (en) | 2013-03-14 | 2020-07-02 | Children's Healthcare Of Atlanta, Inc. | Recombinant RSV with silent mutations, vaccines, and methods related thereto |
US9060975B2 (en) * | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
DE102013004595A1 (de) * | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
EP2983708A4 (en) * | 2013-04-08 | 2016-10-05 | Medimmune Llc | VACCINE COMPOSITION AND METHOD OF USE |
AP2015008815A0 (en) * | 2013-04-25 | 2015-10-31 | Crucell Holland Bv | Stabilized soluble prefusion rsv f polypeptides |
MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
EP3024483B1 (en) | 2013-07-25 | 2020-01-15 | Calder Biosciences Inc. | Conformationally stabilized rsv pre-fusion f proteins |
SG11201600709TA (en) | 2013-08-05 | 2016-02-26 | Glaxosmithkline Biolog Sa | Combination immunogenic compositions |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
US11571472B2 (en) | 2014-06-13 | 2023-02-07 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
CN107405395A (zh) * | 2015-03-17 | 2017-11-28 | 红杉科学有限公司 | 疫苗与佐剂的组合物以及治疗尿路感染的方法 |
JP7189014B2 (ja) | 2015-07-07 | 2022-12-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Rsvに対するワクチン |
EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
WO2017040387A2 (en) * | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
CN114617959A (zh) | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
AU2016379097C1 (en) | 2015-12-23 | 2021-04-08 | Pfizer Inc. | RSV F protein mutants |
WO2017172890A1 (en) | 2016-03-29 | 2017-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substitutions-modified prefusion rsv f proteins and their use |
JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Rsvに対するワクチン |
DK3439672T3 (da) | 2016-04-05 | 2021-02-15 | Janssen Vaccines & Prevention Bv | Stabiliserede opløselige præfusions-rsv-f-proteiner |
CN106124767A (zh) * | 2016-05-12 | 2016-11-16 | 广州瑞辉生物科技股份有限公司 | 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法 |
ES2836598T3 (es) | 2016-05-30 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Proteínas F de RSV prefusión estabilizadas |
TWI634899B (zh) * | 2016-11-22 | 2018-09-11 | 國立臺灣大學 | 包含類b肝病毒顆粒作為佐劑的疫苗組成物 |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
JP2020519663A (ja) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Rsv感染に対する防御免疫を誘導するための方法及び組成物 |
BR112019025193A2 (pt) | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução |
US12083228B2 (en) | 2017-07-24 | 2024-09-10 | Novavax, Inc. | Methods and compositions for treating respiratory disease |
CN111163799A (zh) * | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
JP2020532953A (ja) | 2017-08-07 | 2020-11-19 | カルダー・バイオサイエンシズ・インコーポレイテッド | コンフォメーションが安定化されたrsv融合前fタンパク質 |
US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
KR20200115567A (ko) | 2018-01-29 | 2020-10-07 | 머크 샤프 앤드 돔 코포레이션 | 안정화된 rsv f 단백질 및 그의 용도 |
BR112020019108A2 (pt) | 2018-03-19 | 2020-12-29 | Novavax, Inc. | Vacinas polivalentes de nanopartículas de influenza |
US11576960B2 (en) * | 2018-03-30 | 2023-02-14 | Georgia State University Research Foundation, Inc. | Respiratory syncytial virus (RSV) vaccines |
EP3773704A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic respiratory syncytial virus polypeptides |
BR112021000965A2 (pt) | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
KR20200050264A (ko) * | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
CN109694400A (zh) * | 2019-01-31 | 2019-04-30 | 苏州高泓利康生物科技有限公司 | 一种表达呼吸道合胞病毒f蛋白及其制备方法 |
US20220195016A1 (en) * | 2019-04-18 | 2022-06-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Biological and synthetic molecules inhibiting respiratory syncytial virus infection |
EP3980044A1 (en) | 2019-06-05 | 2022-04-13 | GlaxoSmithKline Biologicals SA | Saponin purification |
US20230054711A1 (en) * | 2019-12-31 | 2023-02-23 | Xiamen University | Multimerization delivery system for intracellular delivery of molecule |
JP7554837B2 (ja) * | 2020-02-27 | 2024-09-20 | 華輝安健(北京)生物科技有限公司 | 可溶性ace2及び融合タンパク質、並びにその適用 |
WO2021249009A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine compositions, methods, and uses thereof |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
CN114685676B (zh) * | 2020-12-28 | 2024-02-13 | 兰州生物制品研究所有限责任公司 | 一种重组蛋白及其表达方法、纯化方法及用途 |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
WO2023237649A1 (en) * | 2022-06-10 | 2023-12-14 | Glaxosmithkline Biologicals Sa | Rsv vaccination with trimeric rsv f fusion protein |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024078597A1 (en) * | 2022-10-13 | 2024-04-18 | Rvac Medicines (Us) , Inc. | Rsv f protein variants and uses thereof |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
WO2024127181A1 (en) | 2022-12-11 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
WO2024155561A2 (en) * | 2023-01-17 | 2024-07-25 | The Scripps Research Institute | Engineered paramyxovirus soluble fusion (f) proteins and related vaccines |
US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
WO2024175579A1 (en) * | 2023-02-21 | 2024-08-29 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain |
CN117304278B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117304280B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
Family Cites Families (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US118A (en) | 1837-02-10 | Improvement in the machine for weighing heavy bodies | ||
US119A (en) | 1837-02-10 | Improvement in the machine for weighing heavy bodies | ||
US139A (en) | 1837-03-11 | Robert wilson | ||
US4186745A (en) | 1976-07-30 | 1980-02-05 | Kauzlarich James J | Porous catheters |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
ATE67769T1 (de) | 1983-01-25 | 1991-10-15 | Ciba Geigy Ag | Neue peptidderivate. |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
US5639853A (en) | 1987-09-29 | 1997-06-17 | Praxis Biologics, Inc. | Respiratory syncytial virus vaccines |
US5194595A (en) | 1987-12-23 | 1993-03-16 | The Upjohn Company | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
ATE157012T1 (de) | 1989-11-03 | 1997-09-15 | Univ Vanderbilt | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
CA2104782C (en) | 1991-03-01 | 2001-08-07 | John F. Gerster | 1-substituted, 2-substituted 1h-imidazo-[4,5-c]quinolin-4- amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
MY111880A (en) | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
CA2151597A1 (en) | 1993-01-08 | 1994-07-21 | Robert L. Garlick | Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
ATE204762T1 (de) | 1993-03-23 | 2001-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
WO1995002597A1 (en) | 1993-07-15 | 1995-01-26 | Minnesota Mining And Manufacturing Company | IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
CZ290331B6 (cs) | 1993-11-17 | 2002-07-17 | Laboratoires Om S. A. | Glukosaminové disacharidy, způsob jejich přípravy a farmaceutický prostředek |
US5397307A (en) | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
JP3403233B2 (ja) | 1994-01-20 | 2003-05-06 | テルモ株式会社 | バルーンカテーテル |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
CA2204254C (en) | 1994-11-17 | 2010-02-16 | Stephen Lewis Hart | Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
PT1005368E (pt) | 1997-03-10 | 2009-11-19 | Coley Pharm Gmbh | Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
US6090619A (en) | 1997-09-08 | 2000-07-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
KR100550132B1 (ko) | 1997-09-19 | 2006-02-08 | 와이어쓰 홀딩스 코포레이션 | 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드 |
WO1999016500A2 (en) | 1997-10-01 | 1999-04-08 | Medtronic Ave, Inc. | Drug delivery and gene therapy delivery system |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
IL138000A0 (en) | 1998-04-09 | 2001-10-31 | Smithkline Beecham Biolog | Adjuvant compositions |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
EP1089913A1 (fr) | 1998-06-08 | 2001-04-11 | SCA Emballage France | Emballage a remise a plat rapide |
RU2223262C2 (ru) | 1998-06-30 | 2004-02-10 | Ом Фарма | Новые ацилированные псевдодипептиды, способ их получения и содержащие их фармацевтические композиции |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
CA2347099C (en) | 1998-10-16 | 2014-08-05 | Smithkline Beecham Biologicals S.A. | Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
ATE276199T1 (de) | 1999-02-03 | 2004-10-15 | Biosante Pharmaceuticals Inc | Methoden zur herstellung von therapeutische kalzium-phosphat partikeln |
ES2308069T3 (es) | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
CN1391483A (zh) | 1999-09-24 | 2003-01-15 | 史密丝克莱恩比彻姆生物有限公司 | 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用 |
AR025749A1 (es) | 1999-09-24 | 2002-12-11 | Smithkline Beecham Biolog | Vacunas |
DK1221955T3 (da) | 1999-09-25 | 2006-01-30 | Univ Iowa Res Found | Immunstimulerende nukleinsyre |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
EP1311288A1 (en) | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
PT1313734E (pt) | 2000-09-01 | 2010-02-09 | Novartis Vaccines & Diagnostic | Derivados aza heterocíclicos e sua utilização terapêutica |
EP1317442B1 (en) | 2000-09-11 | 2005-11-16 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
KR100865706B1 (ko) | 2000-09-26 | 2008-10-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법 |
WO2002042326A1 (en) | 2000-11-22 | 2002-05-30 | Biota Scientific Management Pty Ltd | A method of expression and agents identified thereby |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
CA2435972C (en) | 2001-01-26 | 2011-09-13 | University Of Lausanne | Matrix attachment regions and methods for use thereof |
JP4137640B2 (ja) | 2001-03-09 | 2008-08-20 | アイディー バイオメディカル コーポレイション オブ ケベック | 新規プロテオソーム−リポサッカリドワクチンアジュバント |
ATE404561T1 (de) | 2001-04-17 | 2008-08-15 | Dainippon Sumitomo Pharma Co | Neue adeninderivate |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
PT1719511E (pt) | 2001-11-16 | 2009-03-06 | Coley Pharm Group Inc | N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização |
FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
UA79764C2 (en) | 2001-11-27 | 2007-07-25 | Anadys Pharmaceuticals Inc | 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
CA2477235A1 (en) | 2002-02-21 | 2003-09-04 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
IL164302A0 (en) | 2002-03-29 | 2005-12-18 | Chiron Corp | Substituted benzazoles and use thereof as raf kinase inhibitors |
WO2003083095A1 (en) * | 2002-04-03 | 2003-10-09 | Akzo Nobel N.V. | Viral mutants, manipulated in the furin cleavage sites of glycoproteins |
JP2005531599A (ja) | 2002-05-29 | 2005-10-20 | スリーエム イノベイティブ プロパティズ カンパニー | イミダゾ[4,5−c]ピリジン−4−アミンのための方法 |
AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
AU2003268184A1 (en) | 2002-08-23 | 2004-03-11 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
PT2311848E (pt) | 2002-12-23 | 2013-10-03 | Vical Inc | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
CA2511646A1 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
CA2513655C (en) | 2003-01-21 | 2011-11-22 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
CA2520124A1 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
PL1959011T3 (pl) | 2003-10-24 | 2012-07-31 | Selexis Sa | Wysokowydajny transfer genu i ekspresja w komórkach ssaczych przez procedurę wielokrotnej transfekcji sekwencji regionu przylegania do macierzy |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
JP2007531768A (ja) | 2004-03-31 | 2007-11-08 | ニューヨーク・ユニバーシティ | 感染症、癌および自己免疫疾患を治療するための新規な合成c−糖脂質、その合成および使用 |
KR20110132416A (ko) | 2004-04-05 | 2011-12-07 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
US20060024670A1 (en) | 2004-05-18 | 2006-02-02 | Luke Catherine J | Influenza virus vaccine composition and methods of use |
EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
FR2873378A1 (fr) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
ATE493437T1 (de) | 2004-07-23 | 2011-01-15 | Novartis Vaccines & Diagnostic | Polypeptide für die oligomerisierung von antigenen |
EP3312272B1 (en) | 2004-10-08 | 2019-08-28 | The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services | Modulation of replicative fitness by using less frequently used synonymous codons |
GB0422439D0 (en) | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
WO2008061243A2 (en) * | 2006-11-16 | 2008-05-22 | Novavax, Inc. | Respiratory syncytial virus-virus like particle (vlps) |
WO2008114149A2 (en) * | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
EP2164860A2 (en) | 2007-06-06 | 2010-03-24 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
CN101148479A (zh) * | 2007-09-11 | 2008-03-26 | 浙江理工大学 | 一种重组类人胶原蛋白及生物合成方法 |
PL2222710T3 (pl) * | 2007-12-24 | 2017-01-31 | Id Biomedical Corporation Of Quebec | Rekombinowane antygeny rsv |
MY150481A (en) | 2008-03-03 | 2014-01-30 | Irm Llc | Compounds and compositions as tlr activity modulators |
AU2009236585B2 (en) | 2008-04-18 | 2013-03-07 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
EP2313085A2 (en) * | 2008-07-15 | 2011-04-27 | Novartis AG | Immunogenic amphipathic peptide compositions |
WO2010006447A1 (en) | 2008-07-18 | 2010-01-21 | Id Biomedical Corporation Of Quebec | Chimeric respiratory syncytial virus polypeptide antigens |
DK2370099T3 (en) * | 2008-12-09 | 2016-08-01 | Novavax Inc | Rsv f modified proteins and methods of their use |
WO2010077712A1 (en) | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Bovine respiratory syncytial virus virus-like particle (vlps) |
US8889146B2 (en) | 2009-06-24 | 2014-11-18 | Glaxosmithkline Biologicals, Sa | Vaccine |
BRPI1015917A2 (pt) | 2009-06-24 | 2019-08-27 | Glaxosmithkline Biologicals Sa | antígenos de rsv recombinantes. |
HUE058971T2 (hu) * | 2009-07-15 | 2022-09-28 | Glaxosmithkline Biologicals Sa | RSV F fehérjekészítmények és eljárások azok elõállítására |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
BR112013024157A2 (pt) | 2011-03-22 | 2016-12-06 | Mucosis Bv | composições imunogênicas em forma particulada e métodos para produção destas |
ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
ES2395677B1 (es) | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
MX2017004769A (es) | 2014-10-15 | 2017-10-16 | Amgen Inc | Elementos promotores y reguladores para mejorar la expresion de genes heterologos en celulas hospederas. |
WO2018176103A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | "chimeric molecules and uses thereof" |
-
2010
- 2010-07-15 HU HUE16190004A patent/HUE058971T2/hu unknown
- 2010-07-15 AR ARP100102599A patent/AR077757A1/es unknown
- 2010-07-15 US US13/383,897 patent/US20120164176A1/en not_active Abandoned
- 2010-07-15 EP EP16190004.8A patent/EP3178490B1/en active Active
- 2010-07-15 EP EP22214601.1A patent/EP4218799A1/en active Pending
- 2010-07-15 PT PT161900048T patent/PT3178490T/pt unknown
- 2010-07-15 ES ES16190004T patent/ES2918381T3/es active Active
- 2010-07-15 TW TW099123300A patent/TW201116294A/zh unknown
- 2010-07-15 PL PL16190004.8T patent/PL3178490T3/pl unknown
- 2010-07-15 CN CN201080040594.9A patent/CN102639147B/zh not_active Expired - Fee Related
- 2010-07-15 HR HRP20220756TT patent/HRP20220756T1/hr unknown
- 2010-07-15 EP EP22200670.2A patent/EP4183412B1/en active Active
- 2010-07-15 CN CN201510703646.0A patent/CN105214080A/zh active Pending
- 2010-07-15 JP JP2012520789A patent/JP5829210B2/ja not_active Expired - Fee Related
- 2010-07-15 LT LTEP16190004.8T patent/LT3178490T/lt unknown
- 2010-07-15 RU RU2012105308/10A patent/RU2585227C2/ru not_active IP Right Cessation
- 2010-07-15 US US12/836,931 patent/US20110305727A1/en not_active Abandoned
- 2010-07-15 DK DK16190004.8T patent/DK3178490T3/da active
- 2010-07-15 ES ES10734875.7T patent/ES2563730T3/es active Active
- 2010-07-15 EP EP21199223.5A patent/EP3988115A3/en active Pending
- 2010-07-15 CA CA2768186A patent/CA2768186A1/en not_active Abandoned
- 2010-07-15 EP EP22214608.6A patent/EP4218800A1/en active Pending
- 2010-07-15 SG SG2012002481A patent/SG178026A1/en unknown
- 2010-07-15 SI SI201032111T patent/SI3178490T1/sl unknown
- 2010-07-15 WO PCT/US2010/042161 patent/WO2011008974A2/en active Application Filing
- 2010-07-15 MX MX2012000667A patent/MX2012000667A/es active IP Right Grant
- 2010-07-15 EP EP10734875.7A patent/EP2453918B1/en active Active
- 2010-07-15 BR BR112012001666A patent/BR112012001666A2/pt not_active IP Right Cessation
-
2012
- 2012-01-13 CL CL2012000119A patent/CL2012000119A1/es unknown
- 2012-01-17 CO CO12006115A patent/CO6491045A2/es unknown
-
2015
- 2015-05-08 JP JP2015095502A patent/JP2015145422A/ja active Pending
-
2017
- 2017-08-16 US US15/678,798 patent/US11261239B2/en active Active
-
2021
- 2021-12-29 US US17/564,962 patent/US11820812B2/en active Active
-
2022
- 2022-06-23 US US17/848,205 patent/US11655284B2/en active Active
- 2022-06-23 US US17/848,176 patent/US11629181B2/en active Active
-
2023
- 2023-02-22 US US18/173,006 patent/US11827694B2/en active Active
- 2023-05-24 US US18/323,185 patent/US20230357370A1/en active Pending
- 2023-05-24 US US18/323,215 patent/US20230303669A1/en active Pending
- 2023-05-24 US US18/323,177 patent/US20230357369A1/en active Pending
- 2023-05-24 US US18/323,192 patent/US20230357371A1/en active Pending
- 2023-05-24 US US18/323,209 patent/US20230348575A1/en active Pending
- 2023-05-24 US US18/323,166 patent/US20240034773A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
CY1123152T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
CY1122824T1 (el) | Πρωτεϊνες συντηξης και εμβολια συνδυασμου | |
CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
EA201270062A1 (ru) | Вакцина | |
AU2014310935B2 (en) | Combination vaccine | |
CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
CY1119265T1 (el) | Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου | |
CY1117162T1 (el) | Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης | |
AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
HN2006016512A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
CR10555A (es) | Vacunas para malaria | |
EA201790109A1 (ru) | Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки | |
CO6351811A2 (es) | La proteina de tuberculosis rv2386c, composiciones y usos de la misma | |
TR201905619T4 (tr) | Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri. | |
BR112015011389A2 (pt) | Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica | |
BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
CO6341637A2 (es) | \\\\\\\"composiciones y metodos novedosos\\\\\\\" | |
CO6400198A2 (es) | Composiciones y metodos novedosos | |
CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
DK1949913T3 (da) | Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C | |
EP2762153A3 (en) | Vaccine composition for mucosal administration |